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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Yale’s partnership against Huntington’s disease: an
alumnus reconnects and finds hope as scientists
pursue ‘Viagra for the brain’ and other solutions
The revelation in 1995 that I was at risk for Huntington’s disease, followed
by my positive genetic test for HD in 1999, thrust me into a role as an
activist, a journey to understand the biotechnological frontier, and a fight
for my life.
However, for many years, and even after “coming out” in a major speech to
scientists in February 2011, HD has remained my radioactive semi-secret
because of the stigma surrounding the disease and my fear of genetic
discrimination.
In those early years of confronting HD, I needed to open up to someone –
and to seek help for the cause. Beyond some branches of my family and my
local HD support group, I turned to the people I trusted most: fellow Yale
University alumni, some close friends, others within a circle of trust. Many
lent a sympathetic ear, offering donations, contacts, and advice.
Above all, they helped me feel less lonely inside the terrible “Huntington’s
closet.”
Dr. Martha Nance, a neurologist in Minneapolis dedicated to finding
treatments for HD, became one of my closest HD confidantes. Brooklynbased journalist Norman Oder suggested the idea for this blog. Editing
nearly every article, Oder has become more than a friend: he is my
Huntington’s alter ego.
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Dr. Martha Nance and Gene Veritas in San Diego, 2007.
Yale’s seal, which includes the Latin phrase “Lux et Veritas” (light and
truth), echoed in my choice of an HD pseudonym, “Gene Veritas,” the
“truth in my genes.”
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Now, in a way I would never have imagined, I have come to rely on Yale
itself in my fight against HD.
At the CHDI Foundation’s Seventh Annual HD Therapeutics Conference,
held February 27-March 1 at the Parker Palm Springs in Palm Springs, CA
(a hotel owned by fellow alum and real estate developer Adam Glick), I
heard exciting news about how scientists in the Yale School of Medicine
will help prepare the way for clinical trials of potential therapies.
(Backed by a group of anonymous donors, the non-profit CHDI once stood
for “cure Huntington’s disease initiative” but today simply represents the
name of the foundation, which focuses exclusively on the search for HD
treatments.)
In my unrelenting drive to translate HD science into understandable
terms, I dubbed these compounds “Viagra for the brain,” a phrase that
refers not to the salacious aspects of the famous drug but to these
compounds’ biochemical similarity to Viagra.
I also decided to visit the scientists’ labs to deepen my understanding of
their crucial work, to offer my assistance, and to give myself a shot of
much-needed hope.
Below, watch my short introductory video of the visit.

Hope for for Huntington's Disease at
Yale University: A Report from Gene
Veritas
from Gene Veritas

04:17

An emotional return to New Haven
I had returned only twice to Yale – in 1983, a year after graduation, and,
during a memorable cross-country trip with my wife and daughter in 2010
in my effort to enjoy life to the fullest before the inevitable symptoms of
HD set in.
This time I arrived in New Haven on May 28 after a two-hour train ride
from Manhattan.
That evening, walking through the Yale campus almost 30 years to the day
after I graduated, I experienced a flood of memories – some painful, some
hilarious, and many, many warm and wonderful.
I remembered the sacrifices my grandparents and parents had made to
help me to attend one of the world’s top institutions of learning. I recalled
how, as the grandson of immigrant grandfathers and the son of workingclass parents, I strived to reach the top academically and then
curehd.blogspot.com/2012/06/yales-partnership-against-huntingtons.html
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professionally.
As I peered into the darkened windows of the Yale Daily News, where I
served as a reporter, I wondered whether my 12-year-old daughter, who
writes well and recently sent letters to 35 U.S. Senators about my plight
and the need to reverse their opposition to health care reform, might
herself someday become a journalist. I imagined the two of us critiquing
news articles together. She’s finishing up sixth grade this month, and she
says she wants to attend Yale. I imagined her striding confidently through
the offices.
It seemed almost yesterday when I walked to classes and debated and
laughed with friends in the dining halls of the university’s grand gothic
buildings. Once imposing, they no longer felt intimidating. Life is fast, I
thought with a tinge of sadness.
My life was abruptly sidetracked by HD. My mother died in 2006, and my
father, with a broken heart, followed her in 2009. I wondered: will HD
prevent me from helping my daughter apply for college and begin her own
path in life?
Yale has generated many of America’s leaders, and it inspires leadership in
various ways. I pondered how I had to rise, along with many others, to an
unexpected leadership role in the fight against the disease. And I reminded
myself that I must do my part to keep the flame of leadership burning,
within myself, for as long as I can; within my family; and within the HD
movement.
Back in my hotel room later that evening, I prepared for the next day’s
emotionally charged meetings at the School of Medicine. It was a place I
didn’t go to as an undergraduate, I thought, and represented a new phase
in my HD activism, in my relationship with Yale, and in my life. These
scientists could help save me.
Catching the disease early
As part of a global effort to eradicate HD, the Yale scientists will play an
important role in investigating some of the disorder’s mysteries and in
seeking effective treatments. The university’s faculty in neuroscience,
neuropharmacology, and other fields provide a supportive context for this
work.
Two of the scientists, Hoby Hetherington, Ph.D., and Doug Rothman,
Ph.D., are starting groundbreaking work on important facets of HD.
Dr. Hetherington will apply his knowledge of epilepsy, brain trauma, and
brain scans to study an energy deficit in HD resulting from insufficient
adenosine triphosphate, the basic fuel for our cells.
Using Yale’s 7 Tesla MRI scanner, one of only a few dozen in the world
with ultra-powerful magnets, Dr. Hetherington will scan humans using a
method called MRSI (magnetic resonance spectroscopic imaging).
Dr. Hetherington hopes to determine whether the energy deficit in HD is a
cause or an effect and, in the process, to produce a clearer picture of the
disease as it actually occurs.
MRSI involves the MRI machine augmented with two pieces of additional
equipment – a head detector and shim insert – permitting him to track the
energy deficit by obtaining clear, high-resolution images of study
participants’ brains.
As Dr. Hetherington explained, the detector allows him to adjust the
readouts of each scanned individual’s brain by accounting for distortions
in the magnetic field caused by the presence of the head. It also accounts
curehd.blogspot.com/2012/06/yales-partnership-against-huntingtons.html
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for the heat generated by the head. Using the detector, he can contour the
magnetic field and also pick specific regions of the brain to excite.
Dr. Hetherington’s lab designed and built the first generation of the
detector and continues to develop and test new versions of the device. The
detector is now in commercial development for more widespread use.
Dr. Hetherington will use the detector in his planned study of genepositive, asymptomatic HD people like me.

Dr. Hoby Hetherington places a special head detector in the 7 Tesla MRI
scanner in his lab at Yale University (photo by Gene Veritas).

Dr. Hetherington explains the innards of the head detector (photo by
Gene Veritas).
To compensate in yet another way for distortions in the scanner’s magnetic
field, Dr. Hetherington employs the shim insert, which he also helped to
design. Like a common shim used to straighten objects in woodwork or
masonry, the shim insert levels out the scanner’s magnetic field. He uses
the shim to do the opposite of what the head of the scanned individual
does to the field. This makes the field uniform and thus easier to read.
A standard scanner shim typically can do eight adjustments, Dr.
Hetherington explained. Yale’s can do about 30.
This shim will play an important part in Dr. Hetherington’s HD scans, in
which he will examine areas of the brain (such as the basal ganglia) where
distortions are created by the presence of the sinuses and the ear canals.
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Dr. Hetherington and the shim insert (photo by Gene Veritas)

Dr. Hetherington explains an actual anatomical image of the brain
obtained from the 7 Tesla scanner (photo by Gene Veritas).
“It’s catching the pathology before it’s become lethal or progressed,” Dr.
Hetherington said of his lab’s technology during my visit while showing me
images from an epilepsy study. “That’s the idea of trying to have an early
marker of what’s going on. If the cells have died already, the structure gets
small. You can see that on standard anatomical imaging, but that’s kind of
too late.”
Boosting creatine
Looking ahead 50 to 100 years, Dr. Hetherington speculated that patients
with brain-based disorders such as HD and epilepsy may take a common
drug to correct the problems they cause in bioenergetics.
Dr. Hetherington explained that the HD study will seek to measure
phosphocreatine levels in the brain. Brain cells produce phosphocreatine,
which is essential in bioenergetics, from creatine, which is also created by
the body and can be taken in the form of a supplement.
Beginning with my participation in the Huntington’s Disease Drug Works
(HDDW) program, I have taken creatine for nearly a decade in an effort to
stave off symptoms. Creatine is currently under study in an HD clinical
trial. (Click here to read more about HDDW founder Dr. LaVonne
Goodman's latest assessment of creatine and other supplements.)
curehd.blogspot.com/2012/06/yales-partnership-against-huntingtons.html
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“If you can boost the whole pool (of creatine), you’ll have more
phosphocreatine around,” Dr. Hetherington said of the theory behind
creatine supplementation.
Paralleling mice and humans
Supported by CHDI, Dr. Doug Rothman, Ph.D. a pioneer in the use of
magnetic resonance spectroscopy (MRS) and the Director of Magnetic
Resonance at Yale, will employ MRS to examine another kind of energy
deficits in the mitochondria, the powerhouses of the cell, in transgenic
mice.
HD patients often need a higher-than-average caloric intake.
Rothman’s work could provide important clues as to how Huntington’s
kills brain cells – and what treatments might stop it. He hopes to extend
the experiment to humans, beginning with a 4 Tesla scanner and perhaps
later using the 7 Tesla scanner and its accessories.
“It’s really important to keep an eye on what are the relevant aspects of a
mouse model,” Dr. Rothman commented, noting that transgenic animals
can manifest symptoms differently than humans, and that the
mitochondria are more evolved in humans than in mice. “The only way to
do that is to really explore, hopefully in parallel, what’s happening with
human subjects.”

Dr. Rothman at work in his office (photo by Gene Veritas)
Alleviating symptoms, strengthening the brain
Also with support from CHDI, two other Yale research groups will assess
compounds that, if successful, would improve memory and cognition,
arrest some of the psychiatric symptoms, and act as neurotrophins, socalled “fertilizers” for the brain. At least one of these neurotrophins
(BDNF, brain-derived neurotrophic factor) is severely deficient in HD.
As noted above, I dubbed these substances, developed by Viagra producer
Pfizer, “Viagra for the brain” because the substances belong to the same
class of drug as Viagra, an inhibitor of an enzyme known as a
phosphodiesterase (PDE).
Although targeting different PDE families than the PDE-5 targeted by
curehd.blogspot.com/2012/06/yales-partnership-against-huntingtons.html
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Viagra, the biochemistry is very similar. Essentially, the new compounds
are cousins of Viagra, aiming to inhibit other PDEs.
The Yale scientists will test these compounds in collaboration with CHDI’s
“drug hunters” and Pfizer. One coordinator of the three-way partnership is
Ladislav Mrzljak, M.D., Ph.D., CHDI’s director of neuropharmacology and
a former postdoctoral fellow in Yale’s Department of Neurobiology.
Scientists hope that inhibition of PDEs will compensate for some of the
changes occurring in HD.
With new research showing that some PDE inhibitors reverse symptoms in
mice, CHDI and Pfizer recently began collaborating with the ultimate goal
of taking them into clinical trials.
“There are currently no PDE inhibitors marketed for central nervous
system diseases,” Christopher Schmidt, Ph.D., a senior director at Pfizer,
explained. “This is new territory.”
Mihaly Hajos, Pharm.D., Ph.D., a former Pfizer scientist and
neurophysiologist with a background studying schizophrenia and
Alzheimer’s disease, aims to detect whether the same inefficient use of the
brain’s information processing (a so-called “auditory gating deficit”) that
occurs in humans with HD also occurs in mice and rats genetically
engineered to have the disease. If so, Hajos will then test PDE inhibitors as
a remedy.
The experiment also could validate the electrical signals as a good
biomarker, or measure, of the inhibitors’ impact on people.

Dr. Mihaly Hajos (center) with assistants Elizabeth Arnold and Dr. David
Nagy (photo by Gene Veritas)
Studying nonhuman primates
Another project involves the husband-wife team of Graham Williams,
D.Phil., and Stacy Castner, Ph.D., neuroscientists in the Department of
Psychiatry who are specialists on schizophrenia and substances known as
“cognitive enhancers.” The duo will test the effects of PDE inhibitors on
cognition in normal, healthy nonhuman primates. These subjects contrast
sharply with the transgenic, diseased mice, rats, flies, and even sheep and
pigs used in other Huntington’s research.
“We can’t be dependent on the genetic model,” Dr. Williams explained,
emphasizing the need to view the disease and the effect of potential drugs
from various perspectives.
If the inhibitors work, Drs. Williams and Castner will submit the animals
to harmless brain scans using FDG-PET to localize areas of the brain
affected. These measurements could help predict the impact of the
curehd.blogspot.com/2012/06/yales-partnership-against-huntingtons.html

7/10

11/18/21, 10:29 AM

At Risk for Huntington's Disease: Yale’s partnership against Huntington’s disease: an alumnus reconnects and finds hope as sci…

inhibitors in humans.
Successful studies in the nonhuman primates could help to accelerate the
process of getting the inhibitors into human trials and ultimately approved
as drugs, a process that could take five to ten years.
The PDE inhibitor projects seek ways to intervene early in the disease,
before disabling symptoms occur. The potential therapies could help
prolong my life and the lives of tens of thousands of gene-positive and
symptomatic individuals.
A key workshop: from animals to humans
On May 31 and June 1, I observed yet another aspect of Drs. Williams and
Castner’s research by participating with them in a CHDI meeting in
Manhattan titled “Translatability of Cognitive Readouts Workshop.” With
some two dozen participants and organized by Dr. Allan Tobin, one of
CHDI’s two chief scientific advisors, the workshop aimed to help CHDI
move from testing of potential treatments in animals to human clinical
trials.
Dr. Mrzljak also took part, as did Dr. Ethan Signer, CHDI’s other chief
scientific advisor, Dr. David Howland, director of in vivo biology, and Dr.
Beth Borowsky, director of translational medicine. Robi Blumenstein, the
president of CHDI’s sister management firm, kicked off the meeting.
CHDI will release the conclusions of the workshop in the near future.
Watch my short interview about the meeting with Dr. Tobin in the video
below.

Moving from Animals to Humans in
Huntington's Disease Research: An
Interview with Dr. Allan Tobin
from Gene Veritas

08:12

The workshop was quite intense and intimate, to say the least. Sitting at a
table with one another for eight hours on two consecutive days, and
sharing dinner and drinks in lower Manhattan the evening of May 31, we
formed new friendships and professional relationships. Dr. Tobin
purposely plans the workshops in this way to extract the maximum of
candor and new ideas.
I was invited to the meeting as an “observer.” I thought I would quietly sit
in the back and take notes.
However, to my surprise, Dr. Tobin seated me at one of the heads of the
workshop table. Just before the event began at 9 a.m. on May 31, he asked
if I would mind sharing my story with the scientists, and to be
“interviewed” by Dr. Julie Stout, an American HD researcher based in
Australia.
curehd.blogspot.com/2012/06/yales-partnership-against-huntingtons.html
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A number of the invitees, such as Drs. Williams and Castner, had devoted
their careers to non-HD conditions and questions, so for many in the room
I was a first contact with a person from an HD-affected family.
What I expected to be a few minutes of introduction to the disease turned
into a 90-minute discussion about the many social ramifications of the
disease. In an effort to contribute to the questions of translatability and
cognition, I described such symptoms as my mother’s depression, her loss
of the ability to work, her inability to interact with her granddaughter and
other family members, and the ways in which our family and her
physicians attempted to deal with her symptoms. I also spoke about the
fear surrounding genetic testing.
Dr. Stout commented that telling my story helped the scientists
understand what it’s like to live with HD. Scientists, she observed, need the
collaboration of those confronting HD in the quest for solutions.
At the end of the workshop, I thanked Dr. Tobin, CHDI, and the scientists
for allowing me to share my story – which, I pointed out, was just one of
thousands of such stories one could hear from the HD community.

CHDI translatability workshop participants, with Gene Veritas standing
in back of room (photo by Jerry Turner, CHDI)
Yale and the big picture
Together with CHDI and Pfizer, Yale scientists will furnish pieces of a very
large and complex Huntington’s puzzle currently under study by
researchers throughout the world in academic labs, pharmaceutical
companies, and medical clinics. CHDI, as well as governments and other
organizations, supports many of those projects in producing what most
scientists project as an “HD cocktail” of therapies for managing the disease
and allowing those affected to lead normal and productive lives. (Scientists
don’t speak of “curing” HD, because of its immense complexity and the fact
that the defective gene cannot be removed from the body.)
The path, however, isn’t simple. At Yale, Drs. Hetherington and Rothman
voiced concern about the potential lack of volunteers for their research
involving brain scans. Indeed, stigma and other factors threaten to leave
scientists with too few research participants in which to adequately test
drugs for safety and efficacy. Tragically, the drive to halt Huntington’s
could stall. I pledged to help spread the word of the scanning studies in the
Huntington’s community.
In the quest for treatments, scientists and patients depend on each other.
Likewise, the many disease communities share a mutual goal. By helping
to solve Huntington’s, Yale’s scientists will also assist those fighting
Alzheimer’s, Parkinson’s, and many other conditions that afflict millions –
as well as the estimated tens of millions of victims of thousands of other
curehd.blogspot.com/2012/06/yales-partnership-against-huntingtons.html
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genetic and orphan conditions, the focus of Yale’s new Center for the Study
of Mendelian Disorders.
Yale, its alumni, and its scientists have lent an enormous hand in my
family’s fight. I have already gained strength and support from a network
of Yale ties. Someday I may take a Huntington’s drug tested in a Yale lab.
The place that ignited my intellectual passion and launched me into life
once again holds one of the keys to my future. This is the American
university at its best – engaging in cutting-edge drug discovery, aiding a
community long beleaguered by stigma and hopelessness, and affirming
life.
Posted by Gene Veritas at 11:37 AM
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